Hasil Pencarian  ::  Simpan CSV :: Kembali

"Tesis ini membahas tentang perbedaan ketahanan hidup 5 tahun pasien leukemia akut tipe LLA dan LMA di RSKD dengan menggunakan desain kohort retrospektif. Data didapatkan dari data rekam medis pasien leukemia anak di RSKD yang didiagnosis tahun 1997-2008. Pengumpulan data dilakukan secara retrospektif dengan mengikuti subjek untuk meneliti kejadian yang belum terjadi sejak pertama didiagnosis di RSKD hingga pengamatan berakhir Juni 2012. Rancangan penelitian dibatasi waktu 5 tahun untuk terjadinya event. Dari 95 pasien leukemia akut pada anak didapatkan probabilitas ketahanan hidup keseluruhan sebesar 22,6%, angka ketahanan hidup 5 tahun untuk tipe LMA 4,6%, dan tipe LLA 28,9%. Risiko kematian (HR) setelah 5 tahun pada LMA 1,643 kali dibandingkan LLA.

---

The focus of this study is the differences of five years survival rate of patients with ALL and AML at RSKD using retrospektif cohort design. Data obtained from medical records of patients that diagnosed in 1997-2008. The data was collected retrospectively with the following subjects to investigate since it was first diagnosed at RSKD until observations ended on June 2012. The study design limited period of 5 years until the event occured. The result from this study are 95 patients of acute leukemia in children found the overall five years survival rate is 22,6%, five years survival rate of AML is 4,6%, and five years survival rate of ALL is 28,9%. Hazard Ratio of AML is 1,643 times than ALL."

"Pengobatan pada anak Leukemia limfoblastik akut terus dikembangkan, saat ini di Indonesia ada beberapa protokol yang lazim digunakan yaitu protokol Nasional Jakarta, protokol WK-LLA 2000, protokol LLA 2006 dan protokol LLA 2013. Tujuan studi ini untuk mengetahui probabilitas kesintasan hidup 3 tahun pada anak leukemia limfoblastik akut antara protokol 2006 dan 2013. Studi ini menggunakan mix method yaitu kohort retrosfektif dan wawancara mendalam. Populasi dalam penelitian ini adalah anak LLA usia 1-15 tahun yang mendapatkan protokol 2006 dan 2013 di RSKD Jakarta dari tahun 2008 ndash; 2016 sebanyak 68 anak dengan waktu penelitian dari April 2016 sampai Juni 2016. Data dianalisis dengan menggunakan Cox Regression. Hasil studi ini didapatkan probabilitas kesintasan 3 tahun anak LLA berdasarkan protokol pengobatan 2006 dan 2013 HR 1,57 CI 90 0,577 ndash; 4,299, namun perbedaan antara kedua protokol ini tidak bermakna secara statistik dengan p-value 0,456. Hasil wawancara mendalam juga didapat pada protokol 2006 dan 2013 secara prinsip sama namun tetap ada beberapa perbedaan diantara keduanya seperti jadwal pengobatan dan dosis secara kumulatif meningkat. Kesimpulan yang didapat ada interaksi waktu pada variabel trombosit, kedua protokol ini secara prinsip sama dan tidak terdapat banyak perbedaan dalam hal input dan proses.

---

Treatment of children with Acute lymphoblastic leukemia was developing, currently in Indonesia there are several commonly used protocols such as National protocol Jakarta, WK LLA 2000 protocol, LLA protocol 2006 and protocol LLA 2013. The purpose of this study to determine the probability of survival 3 years In children with acute lymphoblastic leukemia between protocols 2006 and 2013. This study used a mix method of retrospective cohorts and in depth interviews. The population in this study were LLA children aged 1 15 years who received protocol 2006 and 2013 in RSKD Jakarta from 2008 2016 is 68 children with research time from April 2016 until June 2016. Data were analyzed using Cox Regression.

The result of this study shows the probability of 3 year survival of LLA children based on treatment protocol 2006 and 2013 HR 1,57 CI 90 0,577 ndash 4,299, but the difference between these two protocols was not statistically significant with p value 0.456. The results of in depth interviews were also obtained in protocols 2006 and 2013 in the same principle but there remain some differences between the both of the treatment schedule and doses are cumulatively increased. The conclusion is that there is time interaction on platelet variable, these two protocols are in principle the same and there is not much difference in input and process."

"Leukemia Limfositik Akut (LLA) merupakan jenis kanker yang paling banyak dijumpai pada anak. Penyakit ini berpotensi untuk disembuhkan, tetapi keberhasilan terapinya ditentukan oleh banyak faktor prognosis, salah satunya adalah status remisi pasca terapi induksi. Penelitian ini bertujuan untuk mengetahui gambaran luaran terapi induksi pasien LLA pada anak di RS. Kanker “Dharmais” tahun 2007-2012. Penelitian ini menggunakan data sekunder yaitu rekam medik dan data register pasien LLA. Metode yang digunakan deskriptif case series untuk mengetahui gambaran status remisi dan status kehidupan pasien berdasarkan faktor prognosis. Hasil penelitian menunjukkan bahwa kasus baru LLA tiap tahun cenderung meningkat, diikuti dengan angka kematian yang menurun tiap tahunnya. Dari 87 pasien yang diteliti, terjadi 57,5% kasus hidup dan 42,5% kasus meninggal. Berdasarkan faktor prognosis, status remisi banyak dialami oleh kelompok pasien perempuan, umur 1-<10 tahun, LLA-L1, LLA B-cell, jumlah leukosit 50-000-100.000/mm3, Hb <5 gr/dl, trombosit ≥150.000/mm3, dan melakukan terapi induksi sesuai jadwal. Pasien yang berstatus hidup hingga saat penelitian dilakukan banyak dialami pada kelompok perempuan, umur 1- <10 tahun, LLA-L1, LLA B-cell, leukosit <10.000/mm3, Hb≥10gr/dl, trombosit ≥150.000/mm3, melakukan terapi induksi sesuai jadwal, dan berstatus remisi. Event free survival berdasarkan status remisi pada pasien ini adalah 47,1%. Perlu dilakukannya evaluasi terhadap pengobatan yang digunakan saat ini.

---

Acute lymphocytic leukemia is the common malignancy that occur in children. This disease is potensial to be cured, but the succesfull outcome is depend on many factors, one of them is remission after induction therapy. The aim of this research is to know how the outcome of induction phase based of prognostic factors. This study use a descriptive case-series of 87 patients that have been treated in “Dharmais” Cancer Hospital from January 2007 to December 2012.

The result shows new cases of LLA increased and mortality cases decreased annually. Based on prognostic factors, remission occuring mostly in female, age between 1-<10 years old, L1 type, LLA B-cell, WBC count 50.000-100.000/mm3, Hb count <5 gr/dl, trombocyte count ≥150.000/mm3, and compliance schedule of therapy.

Patients that survived occuring in female, age between 1-<10 years old, L1 type, LLA B-cell, WBC count <10.000/mm3, Hb count ≥10 gr/dl, thrombocytes count ≥150.000/mm3, compliance schedule of therapy, and that reach remission after induction phase. Event free survival based of remission is to 47,1% among them. It’s necessary to evaluate the treatment program."

"Leukemia mieloblastik akut (LMA) merupakan kelainan sel punca hematopoetik yang dikarakterisasi oleh ekspansi progenitor mieloid yang tidak terdiferensiasi. Mutasi NPM1 ekson 12 merupakan perubahan genetik yang paling sering diketahui pada pasien LMA dengan kariotipe normal. Saat ini belum ada penelitian tentang mutasi ekson 12 gen NPM1 tipe A pada populasi Indonesia, sehingga belum ada data dan laporan mengenai mutasi ekson 12 gen NPM1 tipe A pada populasi orang Indonesia. Penelitian ini memiliki tujuan umum yaitu mengetahui karakteristik mutasi ekson 12 gen NPM1 pada pasien LMA dewasa di RSCM dan RSKD dan tujuan khusus yaitu mengetahui frekuensi kejadian mutasi tipe A pada ekson 12 gen NPM1 dan mengetahui benar atau tidaknya bahwa mutasi tersebut ditemukan pada pasien LMA dewasa di RSCM dan RSKD dengan kariotipe normal. Penelitian bersifat deskriptif dengan desain potong lintang. Sampel diperiksa dengan teknik ASO-RT-PCR dan hasil negatif dilanjutkan dengan seminested-ASO-RT-PCR. Hasil penelitian memperlihatkan 8 sampel (24,24%) dari total 33 sampel terdeteksi positif mengalami mutasi tipe A dan mutasi tersebut lebih banyak ditemukan pada pasien LMA dewasa di RSCM dan RSKD dengan kariotipe abnormal. Saran dari penelitian ini yaitu perlu dilakukan studi dengan jumlah sampel lebih banyak dan perlu dilakukan sequencing untuk mengetahui tipe mutasi lain dari ekson 12 gen NPM1.

---

Acute Myeloid Leukemia (AML) is a hematopoietic stem cell disorders characterized by expansion of myeloid progenitors that are not differentiated. Exon 12 NPM1 mutations are the most frequent genetic alterations detected in AML patients with normal karyotype. Currently there is no study on type A exon 12 NPM1 gene mutation in Indonesian population. The general objective of this study was to determine the characteristic of exon 12 NPM1 gene mutation in adult AML patients at RSCM and RSKD. While the specific objectives were to determine the frequency of type A exon 12 NPM1 gene mutation and to observe if this mutation was found on adult AML patients with normal karyotype.

This research was designed as a cross sectional descriptive study. Samples were examined for type A mutation in exon 12 NPM1 gene using ASO-RT-PCR technique followed by seminested-ASO-RT-PCR for samples showing negative result. From this study, we found that 8 samples (24.24%) from a total of 33 samples were positively detected for type A mutation. In addition, we also found that this mutation was more frequent in adult AML patients with abnormal karyotype. Further study with larger number of samples and analysis by DNA sequencing is needed to better characterize this type A mutation and to find other type of mutation in exon 12 NPM1 gene respectively."

"Karya ilmiah akhir ini merupakan praktik klinik lanjut keperawatan medikal bedah pada kasus keganasan yang terdiri dari pengelolaan kasus utama Leukimia Myeloid Akut dan 30 resume menggunakan pendekatan Model Konservasi Levine, penerapan Evidence Based Nursing EBN penggunaan larutan lidah buaya pada pasien leukemia dan limfoma yang menderita stomatitis akibat kemoterapi serta inovasi keperawatan modifikasi pengkajian Malignant Wound Assessment Tool MWAT . Masalah keperawatan terbanyak yang muncul pada konservasi energi adalah nyeri, konservasi integritas struktural adalah resiko tinggi infeksi, konservasi integritas personal adalah cemas dan konservasi integritas sosial adalah hambatan interaksi sosial. Penggunaan larutan lidah buaya mampu menurunkan stomatitis dan nyeri stomatitis pada pasien leukemia yang mendapatkan kemoterapi. Modifikasi pengkajian MWAT dan asuhan keperawatan pada pasien luka kanker diharapkan mampu meningkatkan asuhan keperawatan yang berkualitas.

---

This Scientific report was an advanced medical surgical nursing clinical practice of malignancies cases consist one major case of Acute Myeloid Leukemia and 30 summaries using Levine rsquo s Conservation Model, the application of Evidence Based Nursing EBN applying aloe vera solution in patients with leukemia and lymphoma chemotherapy induced mucositis and nursing innovation Malignant Wound Assessment Tool MWAT assessment modification. The majority of nursing problems that arise on energy conservation was pain, in structural integrity conservation was high risk of infection, in personal integrity conservation was anxiety and social integrity conservation was a social interaction impaired. Aloe vera solution was able to reduce mucositis and pain in patients with leukemia that received chemotherapy. MWAT assessment modifications and nursing care in patients with wound cancer might increase the quality of nursing care."

"Latar belakang dan tujuan: Salah satu fungsi vitamin D adalah mengatur proliferasi dan maturasi sel darah. Beberapa penelitian membuktikan bahwa terdapat hubungan rendahnya kadar vitamin D dengan kejadian dan kesintasan pada pasien LMA. Data terbaru menunjukkan bahwa prevalensi insufisiensi vitamin D di Indonesia lebih dari 50%, meskipun Indonesia termasuk negara dengan paparan sinar matahari yang tinggi. Keadaan ini kemungkinan juga dialami oleh pasien LMA di Indonesia sehingga dapat memperburuk prognosis penyakitnya. Sampai saat ini belum diketahui secara pasti hubungan kadar vitamin D dengan prognosis pasien LMA di Indonesia. Selain vitamin D, beberapa sitokin yang dipengaruhi oleh vitamin D seperti IL-6 (sitokin proinflamasi) dan IL-10 (sitokin antiinflamasi) dapat mempengaruhi regulasi hematopoiesis normal dan keganasan pada pasien LMA. Penelitian ini bertujuan untuk Mengetahui hubungan antara kadar vitamin D, IL-6, IL-10, dan rasio IL-6/IL-10 dengan kesintasan 1 tahun pasien LMA.Metode: Penelitian dengan desain kohort retrospektif dilakukan pada 43 pasien LMA di RSCM dan RS Kanker Dharmais. Sebanyak 43 serum darah pasien LMA dianalisis dengan metode ELISA untuk memperoleh kadar vitamin D, IL-6 dan IL-10. Analisis kesintasan 1-tahun dilakukan dengan Kaplan Meier estimator.Hasil: Tidak terdapat hubungan antara kadar vitamin D (HR: 0.817 95%CI 0.352-1.901), IL-6 (HR: 1.057 95%CI 0.525-2.128), IL-10 (HR: 0.586 95%CI 0.294-1.168) dan rasio IL-6/IL-10 (HR: 0.823 95%CI 0.411-1.646) serum dengan kesintasan 1-tahun pasien LMA. Tidak ada korelasi antara vitamin D dengan kadar kadar IL-6, IL-10, dan rasio IL-6/IL-10.Kesimpulan: Tidak diperoleh hubungan bermakna antara kadar vitamin D, IL-6, IL-10, dan rasio IL-6/IL-10 dengan kesintasan 1-tahun, namun kami menyadari bahwa besar sampel yang digunakan masih jauh dari cukup. Hasil analisis menunjukkan ada tendensi vitamin D merupakan faktor proteksi pada kesintasan 1 tahun, sedangkan ratio IL-6/IL-10 merupakan faktor risiko pada kesintasan 1 tahun.

---

Background and aim: Vitamin D was known to the proliferation and maturation of blood cells. Several studies have shown that there is an association between low vitamin D levels with incidences and survivals of AML patients.Previous data had shown that about half of Indonesian have vitamin D insufficiency, even though Indonesia is a tropical country with high sun exposure. Vitamin D insufficiency might also worsen the condition and prognosis of AML patients in Indonesia. Up to date, the relationship between vitamin D levels and the prognosis of AML patients in Indonesia was not known. Several cytokines related to vitamin D, including IL-6 (pro-inflammatory cytokines) and IL-10 (anti-inflammatory cytokines) might also influence the regulation of hematopoiesis in normal and malignant conditions. Thisstudy was aimed to determine the association between vitamin D concentrations, serum IL-6, IL-10 and the ratio of IL-6/IL-10 with 1-year Survival Rate in Indonesian Acute Myeloblastic Leukemia Patients.

Method: This was a retrospective cohort study done in 43 AML patients in RSCM and RS Kanker Dharmais. We analyzed 43 serum samples for vitamin D, IL-6 and IL-10 concentrations using ELISA. Survival analysis was done using Kaplan Meier estimator.

Result: There was no correlation between the levels of vitamin D (HR: 0.817 95%CI 0.352-1.901), IL-6 (HR: 1.057 95%CI 0.525-2.128), IL-10 (HR: 0.586 95%CI 0.294-1.168) and ratio IL-6/IL-10 (HR: 0.823 95%CI 0.411-1.646) with 1 year survival of AML patients. There was no correlation between vitamin D and levels of IL-6, IL-10 and ratio IL-6/IL-10.

Conclusion: There is no correlation between vitamin D, IL-6, IL-10 and ratio IL-6/IL-10 with 1-year survival of AML patients. No association was found between vitamin D, IL-6, IL-10, ratio IL-6/IL-10. However, the study was done in a limited sample size. Analysis showed a tendency for vitamin D to be a protective factor at 1 year survival, while the ratio IL-6/IL-10 was a risk factor at 1 year survival."

"Tiopurin Metil-Transferase (TPMT) merupakan salah satu enzim yang berperan penting dalam metabolisme 6-merkaptopurin (6-MP) dan telah terbukti secara klinis memiliki pengaruh terhadap efek 6-MP yang digunakan dalam terapi leukemia limfoblastik akut, salah satunya adalah myelosupresi. Aktivitas TPMT ini sangat dipengaruhi oleh varian (polimorfisme) pada gen TPMT. Penelitian ini dilakukan untuk mengetahui pengaruh polimorfisme genetik Tiopurin Metil-Transferase (TPMT) terhadap toksisitas hematologi pada pasien anak leukemia limfoblastik akut (LLA) yang menerima terapi 6-merkaptopurin pada fase maintenance. Penelitian ini dilakukan dengan disain kohort retrospektif. Hasil menunjukkan bahwa terdapat 25 pasien (69,4%) dari 36 pasien mengalami polimorfisme TPMT*2 heterozigot, dan tidak ditemukan adanya polimorfisme TPMT*3A dan TPMT*3C. Pengaruh genotipe tersebut terhadap toksisitas hematologi dianalisis secara statistik menggunakan uji chi-square dan regresi logistik, dan ditemukan bahwa polimorfisme genetik TPMT*2 tidak signifikan mempengaruhi kejadian toksisitas hematologi berupa anemia, leukopenia, dan trombositopenia dilihat dari nilai RR secara berturut sebesar 2,2 (CI: 0,361-13,424); 1,8 (CI: 0,379-8,533); dan 3,4 (CI. 0,320-35,753).

---

Thiopurin methyltransferase (TPMT) is one of the enzymes playing important roles in 6-mercaptopurine metabolism that has been clinically proven to have influence the effects of the drug used in acute lymphoblastic leukemia therapy, one of them is myelosuppression. TPMT activity is strongly influenced by variants (polymorphisms) in the TPMT gene. This study was conducted to determine the effects of genetic polymorphisms of TPMT against hematologic toxicity in pediatric patients with acute lymphoblastic leukemia (ALL) receiving 6-mercaptopurine therapy in the maintenance phase. This study was conducted with a retrospective cohort design. The results showed that there were 25 patients (69.4%) of 36 had heterozygous TPMT*2 polymorphism, and there were no TPMT*3A and TPMT*3C polymorphisms. The effects of genotypes against the hematologic toxicity were analysed using the chi-square test and logistic regression, and it was found that genetic polymorphism of TPMT did not significantly affect the incidence of hematologic toxicity, such as anemia, leukopenia, and thrombocytopenia after being controlled by age, with successive RR of 2.2 (CI: 0.361-13.424); 1.8 (CI: 0.379-8.533); dan 3.4 (CI. 0.320-35.753."

"Leukemia limfoblastik akut (LLA) adalah jenis kanker yang disebabkan oleh akumulasi limfoblas di sumsum tulang yang mempengaruhi banyak anak. Keberhasilan pengobatan pada pasien leukemia dapat dinilai berdasarkan tingkat kelangsungan hidup pasien LLA. Tujuan dari penelitian ini adalah untuk mengidentifikasi kelangsungan hidup 5 tahun, faktor-faktor yang mempengaruhinya, dan nilai skor prediktor kelangsungan hidup pada anak usia 1-18 tahun yang didiagnosis dengan leukemia limfoblastik akut (LLA) di RSAB Harapan Kita. Penelitian ini adalah penelitian observasional analitik yang menggunakan desain penelitian kohort retrospektif. Sampel adalah 130 pasien LLA yang didiagnosis pada tahun 2013-2014 yang diperoleh dari teknik pengambilan sampel non-probabilitas jenis consecutive sampling. Data dikumpulkan dengan melacak rekam medis pasien. Data dianalisis menggunakan analisis Kaplan-Meier dan Regresi Cox. Hasil penelitian menunjukkan bahwa probabilitas tingkat kelangsungan hidup pasien LLA tahun 2013-2014 adalah 92,25% dengan tingkat kelangsungan hidup rata-rata 60 bulan. Berdasarkan analisis multivariat menggunakan model interaksi regresi Cox, faktor yang paling berpengaruh pada tingkat kelangsungan hidup pasien LLA adalah komorbiditas (p = 0,002; HR = 10,76 CI; 2,38-48,55), remisi (p = 0,001; HR = 13,28 CI2,98- 59,73) dan kambuh (p = 0,014; HR = 7,92 CI; 1,53-41,12).

---

Acute lymphoblastic leukemia (LLA) is a type of cancer caused by the accumulation of lymphoblasts in the bone marrow that affects many children. The success of treatment in leukemia patients can be assessed based on the survival rate of LLA patients. The aims of this study were to identify 5-year survival, the factors that influence it, and the scoring value of predictors of survival in children aged 1-18 years diagnosed with acute lymphoblastic leukemia (LLA) in RSAB Harapan Kita. This study is an analytic observational study that used retrospective cohort study design. The sample was 130 LLA patients diagnosed in 2013-2014 who were obtained from a non-probability sampling technique consecutive sampling. Data were collected by tracking the patient's medical records. Data were analyzed using Kaplan- Meier analysis and Cox Regression. The results show that the LLA patient's survival rate probability from 2013-2014 was 92.25% with a median survival rate of 60 months. Based on multivariate analysis using Cox regression interaction models, the most influential factors on survival rate of LLA patients were comorbidity (p = 0.002; HR = 10.76 CI; 2.38-48.55), remission (p = 0.001; HR = 13.28 CI2.98-59.73) and relapse (p = 0.014; HR = 7.92 CI; 1.53- 41.12)"

"ini membahas tentang Pengaruh Gangguan Psikososial pada Pasien Leukemia Yang Menjalani Kemoterapi terhadap Ketahanan Hidup Pasien Leukemia di Instalasi Rawat Inap Rumah Sakit Kanker “Dharmais”. Data didapatkan dari data Rekam Medis dan Observasi penilaian Asuhan Keperawatan pasien Leukemia Acute di RS. Kanker “Dharmais” yang didiagnosa tahun 2007 – 2012, data yang diambil adalah data sejak pertama pasien didiagnosa hingga pengamatan berakhir Mei 2012. Dari 136 pasien didapatkan median lama ketahanan hidup pasien leukimia adalah 25 bulan dengan standar deviasi 22,11 bulan, CI 95% (27,05 - 34,55), yang mengalami gangguan psikososial median lama ketahanan hidup 47 bulan CI 95% (37,57-56,43), umur ≤ 40 tahun median lama ketahanan hidup 53 bulan CI 95% (37,47-68,53), jenis kelamin perempuan 47 bulan CI 95% (27,99-66), Tidak relaps 74 bulan CI 95% (67,36-80,64), Remisi 47 bulan CI 95% (34,06-59,94), jenis leukemia AML 47 bulan CI 95% (35,87-58,13), Kelengkapan pengobatan 53 bulan CI 95% (36,07-69,93) dan asuhan keperawatan kurang baik 56 bulan CI 95% (39,59-72,41). Pada analisa multivariat didapatkan variabel yang berpengaruh terhadap ketahanan hidup adalah jenis kelamin, relaps dan remisi.

---

This thesis discusses the influence of Psychosocial Disorders in patients of Leukemia Undergoing Chemotherapy for Leukemia Patient Survival Inpatient “Dharmais” Cancer Hospital. Data obtained from Medical Record and Observation of patient assessment nursing care of Acute Leukemia in the hospital which was diagnosed in 2007 - 2012, is data since the first patients were diagnosed up to the observation expires May 2012. Of the 136 patients had a median survival time of patients of Leukemia Acute is 25 months with SD 22,11months, CI 95% (27,05-34,55), psychosocial disorders 48 months CI 95% (37,57-56,43), age ≤ 40 years old CI 95% ((37,47-68,5), no relaps 74 months CI 95% ((67,36-80,64), Remission 47 months CI 95% (34,06-59,94), a type of leukemia AML CI 95% ((35,87-58,13), completeness treatment 53 months CI 95% (36,07-69,93) dan nursing care less well 56 bulan CI 95% (39,59-72,41). On Multivariate analysis found is variables effect on survival gender, relaps, remission."

"ABSTRAK Latar Belakang Leukemia limfoblastik akut LLA adalah keganasan paling sering pada anak di sebagian besar dunia insiden bervariasi di berbagai daerah mulai 15 sampai 40 Keberhasilan pengobatan pada LLA dapat dilihat berdasarkan angka kesintasan Rumah Sakit Sanglah telah merawat pasien leukemia anak akan tetapi sampai saat ini belum pernah dilakukan penilaian terhadap kesintasan pada kasus leukemia akut Tujuan Untuk mengetahui angka kesintasan pasien LLA serta faktor faktor yang memengaruhi LLA di bawah umur 12 tahun di RSUP Sanglah dari tahun 2010 2012 Metode Penelitian kohort retrospektif dilakukan di RS Sanglah dengan menggunakan data sekunder dari catatan medis pasien LLA dari Januari 2010 ndash Desember 2012 Sampel adalah pasien berusia 0 12 tahun terdiagnosis LLA kemudian dikelompokkan menjadi risiko biasa dan risiko tinggi berdasarkan nilai leukosit awal usia dan protokol LLA tahun 2006 Hasil Penelitian Terdapat 33 subjek pasien LLA Didapatkan perbedaan bermakna faktor prognostik usia 1 9 tahun dengan usia 9 tahun dan jumlah leukosit 50 000 mL dengan leukosit 50 000 mL memengaruhi angka kesintasan dengan nilai masing masing p 0 023 dan p 0 013 Angka kesintasan hidup secara keseluruhan pasien LLA adalah 30 3 didapatkan perbedaan bermakna angka kesintasan antara RT dan RB dengan nilai masing masing adalah 11 8 43 8 dan p ABSTRACT Background Acute lymphoblastic leukemia ALL is the most common hildhood cancer in the world Incidence rate found various in several countries from 15 to 40 A successful theraphy of ALL be evaluated by the survival rate Sanglah hospital has been treated children with ALL but however a research of survival rate in children with ALL has never been done before Objective To know the survival rate of children with ALL and factors that affect ALL in children under 12 years old that has been treated in Sanglah Hospital from 2010 2012 Method A retrospective cohort study run in Sanglah Hospital using secondary data from medical record of children with ALL between January 2010 December 2012 Sample is ALL patients aged 0 12 years old with diagnosis ALL will be separated into normal risk group and high risk group based on early number of leucosyte age and therapy protokol year 2006 Results There are 33 subjects of children with ALL Significant difference of prognostic factors were found between the age of 1 9 years old and at the age 9 years old as well as between leucocyte count 50 000 mL and those with leucocyte count 50 000 mL affect the survival rate with each p value of p 0 023 and p 0 013 The Overall survival rate of ALL patients was 30 3 There were significant difference of survival rate between RT and RB valued 11 8 43 8 with p;Background Acute lymphoblastic leukemia ALL is the most common hildhood cancer in the world Incidence rate found various in several countries from 15 to 40 A successful theraphy of ALL be evaluated by the survival rate Sanglah hospital has been treated children with ALL but however a research of survival rate in children with ALL has never been done before Objective To know the survival rate of children with ALL and factors that affect ALL in children under 12 years old that has been treated in Sanglah Hospital from 2010 2012 Method A retrospective cohort study run in Sanglah Hospital using secondary data from medical record of children with ALL between January 2010 December 2012 Sample is ALL patients aged 0 12 years old with diagnosis ALL will be separated into normal risk group and high risk group based on early number of leucosyte age and therapy protokol year 2006 Results There are 33 subjects of children with ALL Significant difference of prognostic factors were found between the age of 1 9 years old and at the age 9 years old as well as between leucocyte count 50 000 mL and those with leucocyte count 50 000 mL affect the survival rate with each p value of p 0 023 and p 0 013 The Overall survival rate of ALL patients was 30 3 There were significant difference of survival rate between RT and RB valued 11 8 43 8 with p;Background Acute lymphoblastic leukemia ALL is the most common hildhood cancer in the world Incidence rate found various in several countries from 15 to 40 A successful theraphy of ALL be evaluated by the survival rate Sanglah hospital has been treated children with ALL but however a research of survival rate in children with ALL has never been done before Objective To know the survival rate of children with ALL and factors that affect ALL in children under 12 years old that has been treated in Sanglah Hospital from 2010 2012 Method A retrospective cohort study run in Sanglah Hospital using secondary data from medical record of children with ALL between January 2010 December 2012 Sample is ALL patients aged 0 12 years old with diagnosis ALL will be separated into normal risk group and high risk group based on early number of leucosyte age and therapy protokol year 2006 Results There are 33 subjects of children with ALL Significant difference of prognostic factors were found between the age of 1 9 years old and at the age 9 years old as well as between leucocyte count 50 000 mL and those with leucocyte count 50 000 mL affect the survival rate with each p value of p 0 023 and p 0 013 The Overall survival rate of ALL patients was 30 3 There were significant difference of survival rate between RT and RB valued 11 8 43 8 with p"